This is the area $VHT are collaborating with $MSFT, isn't it? @Nnyck777 have you seen any journal articles reporting outputs form that work?

As Mark Twain said "Rumours of my death have been greatly exaggerated"

Yeah I think so I will need to go hunting see what I can dig up.

OK @Slew, from my quick read, Transpara is a separate entity (nothing to do with $VHT) https://transparabreastcare.com/about-us/. However, interestingly, Professor Sir Michael Brady was one of the founders of Screenpoint, which developed Transpara. Brady was Ralph Highnam's PhD supervisor at Oxford and co-founded the technology that led to the formation of $VHT. Until 2020 he was on the board of $VHT, and according to the 2023 annual report he still holds 2.61% fof shares in $VHT. (so as a deep industry insider, he is still a believer!)

Transpara is focused on using AI to detect breast cancer. The research is showing that it significantly reduces radiologist workload, by helping to prioritise where they focus their attention. (I've seen numbers of 43% saving, which is huge, however, I am not 100% what the statistic relates to.)

Kristina Lang, is also one of the key researchers. She is at Lund University and works with a mamography unit in nearby Malmo. (Lund is a charming little town if you ever get the chance to visit. I worked there on unrelated healthcare issues in the early 2000s.) Kristina is a common link, having published a lot of the key work on breast density using the Volpara Density Score as a key risk indicator. She is also involved in the AI work using Transpara, which was subject of the BBC article. The team appear to be using datasets from the Norweigian screening program, so I think this is directly linked to what Teri was talking about, and it provides some colour around the leadership that the Scandinavians are playing in using advanced technology to improve breast cancer screening.

Science moves at it own pace, so I wouldn't read this as pointing to an immiment national health program announcement (the end goal the Teri spoke about), but it is positive.

Given the rate of publications coming out from top journals this year, pointing to positive results, it certainly seems that momentum is building towards something in Scandinavia. Its not all about $VHT for sure, and there is no guarantee that Volpara Density Score would be included in a national program, but it is clear that $VHT is in the mix. So that's a positive.

All of this is from a very quick scan of several article abstracts, as I am focused on other things at the moment. I don't think at this stage it has valuation implications one way or the other for $VHT. But others may read it differently (and who knows what the market "thinks"). We also have to bare in mind that FDA has already issued its mandate about the role of breast density in screening, so the tailwind is already blowing.

@mikebrisy @Slew good work guys, interesting stuff

So, I have been trying to unravel the link between Transpara and Volpara.

Transpara has a product Screenpoint. In July 2019, Volpara announced an agreement to sell Screenpoint into the US, Aus, NZ and parts of Asia. This explains the crossover of key staff etc mentioned by @mikebrisy above.  Looking in from the outside, it appears there is collaboration between the companies and I surmise that the Transpara study from the EU is a positive for VHT as well.

Transpara is a part of the Volpara scorecard suite on patient risk. Excerpt from article:

https://www.volparahealth.com/news/volpara-showcases-intelligent-breast-cancer-screening-platform-at-ahra/

Volpara^®Scorecard+™ software provides three key patient risk insights, including:

• Breast density. Volpara^®Density^™ software uses artificial intelligence (AI), physics and imaging data to provide radiologists with an automated, objective, volumetric breast density assessment.
• Short-term risk. Transpara^® software by ScreenPoint Medical uses AI to automatically assign each screening mammogram a score from 1 to 10. Exams with a high score are more likely to contain breast cancer.
• Lifetime risk. Volpara^®Risk™ software captures patient information through a simple, easy-to-use interface. VolparaRisk uses that information, along with the VolparaDensity score, to calculate a woman’s lifetime risk of developing breast cancer using the Tyrer-Cuzick Breast Cancer Risk model (TC8).

Great pick-up @Slew I missed that connection. Although now that you mention it, I do remember past $VHT references to Transpara. I agree that positive newsflow on Transpara is good for $VHT.